Search research articles
Contact Us
Filters
Showing results (221-230 of 252) with videos related to
Page
of 26
Sort By:
Journal of Cardiovascular Pharmacology
|
June 1, 1989
Preclinical pharmacology of zofenopril, an inhibitor of angiotensin I converting enzyme
J M DeForrest, T L Waldron, J Krapcho, et al.
Rejuvenation Research
|
November 8, 2007
Differential effects of in vitro zinc treatment on gene expression in peripheral blood mononuclear cells derived from young and elderly individuals
D J Mazzatti, M Malavolta, A J White, et al.
Experimental Gerontology
|
March 31, 2004
Validation of a new highly standardised, lab-independent whole-blood leukocyte function assay for clinical trials (ILCS)
M Schmolz, T L Hurst, D M Bailey, et al.
Experimental Gerontology
|
March 5, 2008
Effects of interleukin-6 -174C/G and metallothionein 1A +647A/C single-nucleotide polymorphisms on zinc-regulated gene expression in ageing
D J Mazzatti, M Malavolta, A J White, et al.
Pharmaceutical Research
|
July 1, 1993
Effect of sodium acid pyrophosphate on ranitidine bioavailability and gastrointestinal transit time
K M Koch, A F Parr, J J Tomlinson, et al.
Antimicrobial Agents and Chemotherapy
|
September 1, 1991
Pharmacokinetics of cefuroxime axetil and cefaclor: relationship of concentrations in serum to MICs for common respiratory pathogens
N C James, K H Donn, J J Collins, et al.
Journal of Cardiovascular Pharmacology
|
November 1, 1989
Fosinopril, a phosphinic acid inhibitor of angiotensin I converting enzyme: in vitro and preclinical in vivo pharmacology
J M DeForrest, T L Waldron, C Harvey, et al.
Journal of Pharmacokinetics and Biopharmaceutics
|
June 1, 1980
Evaluation of the absorption from 15 commercial theophylline products indicating deficiencies in currently applied bioavailability criteria
R A Upton, L Sansom, T W Guentert, et al.
Clinical Pharmacokinetics
|
June 8, 2000
Impact of population pharmacokinetic-pharmacodynamic analyses on the drug development process: experience at Parke-Davis
S C Olson, H Bockbrader, R A Boyd, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
February 12, 1998
Angiotensin-converting enzyme inhibition and angiotensin II subtype-1 receptor blockade during the progression of left ventricular dysfunction: differential effects on myocyte contractile processes
F G Spinale, H H Holzgrefe, R Mukherjee, et al.
Page
of 26
Search research articles
Search
Showing results (221-230 of 252) with videos related to
Sort By:
Page
of 26
Journal of Cardiovascular Pharmacology
|
June 1, 1989
Preclinical pharmacology of zofenopril, an inhibitor of angiotensin I converting enzyme
J M DeForrest, T L Waldron, J Krapcho, et al.
Rejuvenation Research
|
November 8, 2007
Differential effects of in vitro zinc treatment on gene expression in peripheral blood mononuclear cells derived from young and elderly individuals
D J Mazzatti, M Malavolta, A J White, et al.
Experimental Gerontology
|
March 31, 2004
Validation of a new highly standardised, lab-independent whole-blood leukocyte function assay for clinical trials (ILCS)
M Schmolz, T L Hurst, D M Bailey, et al.
Experimental Gerontology
|
March 5, 2008
Effects of interleukin-6 -174C/G and metallothionein 1A +647A/C single-nucleotide polymorphisms on zinc-regulated gene expression in ageing
D J Mazzatti, M Malavolta, A J White, et al.
Pharmaceutical Research
|
July 1, 1993
Effect of sodium acid pyrophosphate on ranitidine bioavailability and gastrointestinal transit time
K M Koch, A F Parr, J J Tomlinson, et al.
Antimicrobial Agents and Chemotherapy
|
September 1, 1991
Pharmacokinetics of cefuroxime axetil and cefaclor: relationship of concentrations in serum to MICs for common respiratory pathogens
N C James, K H Donn, J J Collins, et al.
Journal of Cardiovascular Pharmacology
|
November 1, 1989
Fosinopril, a phosphinic acid inhibitor of angiotensin I converting enzyme: in vitro and preclinical in vivo pharmacology
J M DeForrest, T L Waldron, C Harvey, et al.
Journal of Pharmacokinetics and Biopharmaceutics
|
June 1, 1980
Evaluation of the absorption from 15 commercial theophylline products indicating deficiencies in currently applied bioavailability criteria
R A Upton, L Sansom, T W Guentert, et al.
Clinical Pharmacokinetics
|
June 8, 2000
Impact of population pharmacokinetic-pharmacodynamic analyses on the drug development process: experience at Parke-Davis
S C Olson, H Bockbrader, R A Boyd, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
February 12, 1998
Angiotensin-converting enzyme inhibition and angiotensin II subtype-1 receptor blockade during the progression of left ventricular dysfunction: differential effects on myocyte contractile processes
F G Spinale, H H Holzgrefe, R Mukherjee, et al.
Page
of 26